Craig Parker

Position: Venture Partner

Craig Parker joined The Column Group in 2024 as a Venture Partner. He is CEO of Surrozen. Mr. Parker brings more than 25 years of science and business experience across leadership positions in both public and privately-held biopharmaceutical companies, as well as within financial organizations. Prior to Surrozen, he was Senior Vice President of Corporate Development at Jazz Pharmaceuticals. He previously served as Executive Vice President of Corporate Development and Scientific Affairs at Geron Corporation, as well as Senior Vice President of Strategy and Corporate Development at Human Genome Sciences until the company’s acquisition by GlaxoSmithKline. He began his career in various positions at financial institutions on Wall Street, where he was one of the top-ranked biotechnology research analysts. Mr. Parker serves as a member of the Scientific Advisory Board of Life Sciences Institute, University of Michigan, and chairs the institute’s Leadership Council. He earned a bachelor’s degree in biological sciences from the University of Chicago, an MBA from the University of Michigan and attended the Georgetown University School of Medicine.

Scroll to Top